Johnson Fistel investigates potential derivative claims for aTyr Pharma Inc. (NASDAQ: ATYR) over alleged fiduciary breaches in Phase 3 EFZO-FIT trial disclosures.
Investigations are being carried out by Johnson Fistel, PLLP in San Diego starting December 15, 2025, regarding derivative claims associated with aTyr Pharma, Inc. (NASDAQ: ATYR) involving suspected breaches of fiduciary duties related to the Phase 3 EFZO-FIT clinical trial disclosures. The class action in question pertains to...
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments